Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 7/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1388172 | 1.00 | ALDH1A1 (0.68) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL1388171 | 1.00 | ALDH1A1 (0.68) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL1389074 | 0.86 | PDE4B (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL1389073 | 0.86 | PDE4B (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL1389021 | 0.86 | PDE4B (0.55) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL1389020 | 0.86 | PDE4B (0.55) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL8482836 | 0.85 | PDE4A (0.57) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL8482828 | 0.85 | PDE4A (0.57) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL8481926 | 0.84 | PDE4B (0.55) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A | |
| SCHEMBL7316971 | 0.83 | PDE4B (0.51) | ALDH1A1MAPTHPGDSMN1; SMN2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640070-B1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1997-09-10 | — | — | EP | claimed |
| US-5633257-A | PHOSPHODIESTERASE INHIBITOR | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-27 | — | — | US | claimed |
| JP-H08501801-A | — | — | 1996-02-27 | — | — | JP | claimed |
| EP-0640070-A1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS. | CELLTECH THERAPEUTICS LTD (GB) | 1995-03-01 | — | — | EP | claimed |
| WO-1994020455-A1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-09-15 | — | — | WO | claimed |
| EP-0766671-B1 | TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH R&D LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-20020143011-A1 | Tri-substituted phenyl derivatives and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED | 2002-10-03 | — | — | US | disclosed |
| EP-0766670-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH R&D LTD (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-20010034450-A1 | Tetra-substituted phenyl derivatives and processes for their preparation | ALEXANDER RIKKI PETER (GB) | 2001-10-25 | — | — | US | disclosed |
| EP-0640065-B1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2001-10-17 | — | — | EP | disclosed |
| US-6297264-B1 | E.G., 4-(2-BENZYLOXY-2-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL)ETHYL)PYRID INE; PHOSPHODIESTERASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-10-02 | — | — | US | disclosed |
| US-6245774-B1 | ANTIINFLAMMATORY AGENTS; BRONCHODILATOR AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-06-12 | — | — | US | disclosed |
| US-6197792-B1 | PHOSPHODIESTERASE INHIBITOR | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| EP-0640070-B1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1997-09-10 | — | — | EP | disclosed |
| US-5633257-A | PHOSPHODIESTERASE INHIBITOR | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
| EP-0640070-A1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS. | CELLTECH THERAPEUTICS LTD (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1994020455-A1 | STYRYL DERIVATIVES, THEIR PREPARATION AND USE AS PDE-IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143011-A1 | Tri-substituted phenyl derivatives and processes for their preparation | CBR1, NCOR1, CNR1 | ALDH1A1 2785/4885MAPT 3885/4885HPGD 4511/4885 |
| US-20010034450-A1 | Tetra-substituted phenyl derivatives and processes for their preparation | CBR1, CSNK1A1L, NPY1R | ALDH1A1 3986/4885MAPT 4433/4885HPGD 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.